Premium
Drug‐induced alloreactivity: A new paradigm for allorecognition
Author(s) -
D'Orsogna Lloyd J.,
Almeida CoralAnn M.,
Miert Paula,
Zoet Yvonne M.,
Anholts Jacqueline D. H.,
Chopra Abha,
Watson Mark,
Witt Campbell,
John Mina,
Claas Frans H. J.
Publication year - 2019
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.15470
Subject(s) - allorecognition , abacavir , human leukocyte antigen , immunology , t cell , ctl* , medicine , transplantation , biology , cd8 , antigen , immune system , virus , viral load , antiretroviral therapy
Abacavir administration is associated with drug‐induced hypersensitivity reactions in HIV + individuals expressing the HLA ‐B*57:01 allele. However, the immunological effects of abacavir administration in an HLA ‐B57 mismatched transplantation setting have not been studied. We hypothesized that abacavir exposure could induce de novo HLA ‐B57‐specific allorecognition. HIV ‐specific CD 8 T cell clones were generated from HIV + individuals, using single cell sorting based on HIV peptide/ HLA tetramer staining. The T cell clones were assayed for alloreactivity against a panel of single HLA ‐expressing cell lines, in the presence or absence of abacavir. Cytokine assay, CD 137 upregulation, and cytotoxicity were used as readout. Abacavir exposure can induce de novo HLA ‐B57 allorecognition by HIV ‐specific T cells. A HIV Gag RK 9/ HLA ‐A3‐specific T cell did exhibit interferon‐γ production, CD 137 upregulation, and cytolytic effector function against allogeneic HLA ‐B57, but only in the presence of abacavir. Allorecognition was specific to the virus specificity, HLA restriction, and T cell receptor TRBV use of the T cell. We provide proof‐of‐principle evidence that administration of a drug could induce specific allorecognition of mismatched HLA molecules in the transplant setting. We suggest that HIV ‐seropositive recipients of an HLA ‐B57 mismatched graft should not receive abacavir until further studies are completed.